


PHARMACEUTICAL 2021

XERIS PHARMACEUTICALS INC Rank 269 of 409





PHARMACEUTICAL 2021

XERIS PHARMACEUTICALS INC Rank 269 of 409

The relative strengths and weaknesses of XERIS PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of XERIS PHARMACEUTICALS INC compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 70% points. The greatest weakness of XERIS PHARMACEUTICALS INC is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 103% points.

The company's Economic Capital Ratio, given in the ranking table, is -234%, being 121% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	152,212
Cost of Goods Sold	9,328
Intangible Assets	0
Liabilities, Current	28,207
Liabilities, Non-Current	0
Other Assets	232
Other Compr. Net Income	0
Other Expenses	-110
Other Liabilities	97,183
Other Net Income	-7,424
Property and Equipment	6,707
Research and Development	20,921
Revenues	20,155
Selling, General and Administrative Expense	73,732

Output Variable	Value in 1000 USD
Assets	159,151
Liabilities	125,390
Expenses	103,871
Stockholders Equity	33,761
Net Income	-91,140
Comprehensive Net Income	-91,140
Economic Capital Ratio	-234%